ERBB2 and ovarian neoplasm: To investigate whether the anti-tumor effects of scFvMTBHsp70 was associated with anti-tumor effector CD8+ T-cell responses, we re-stimulated splenocytes from ovarian tumor-bearing FVB mice that received different treatments with the CD8+ T-cell Her2/neu epitope or MSLN Ld1 as a negative control, ex vivo, and analyzed the cells for production of IFNγ and Granzyme B using flow cytometry.